JP7341217B2 - 抗ｃｄ１３７抗体 - Google Patents

抗ｃｄ１３７抗体 Download PDF

Info

Publication number
JP7341217B2
JP7341217B2 JP2021500559A JP2021500559A JP7341217B2 JP 7341217 B2 JP7341217 B2 JP 7341217B2 JP 2021500559 A JP2021500559 A JP 2021500559A JP 2021500559 A JP2021500559 A JP 2021500559A JP 7341217 B2 JP7341217 B2 JP 7341217B2
Authority
JP
Japan
Prior art keywords
antibody
antibody molecule
seq
antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021500559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525546A5 (https=
JPWO2020011968A5 (https=
JP2021525546A (ja
Inventor
ペチョウコヴァ，サルカ
ウォラートン，フランシスカ
ガスパール，ミゲル
Original Assignee
エフ－スター セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ－スター セラピューティクス リミテッド filed Critical エフ－スター セラピューティクス リミテッド
Publication of JP2021525546A publication Critical patent/JP2021525546A/ja
Publication of JP2021525546A5 publication Critical patent/JP2021525546A5/ja
Publication of JPWO2020011968A5 publication Critical patent/JPWO2020011968A5/ja
Application granted granted Critical
Publication of JP7341217B2 publication Critical patent/JP7341217B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2021500559A 2018-07-12 2019-07-12 抗ｃｄ１３７抗体 Active JP7341217B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1811404.1A GB201811404D0 (en) 2018-07-12 2018-07-12 Anti-CD137 Antibodies
GB1811404.1 2018-07-12
PCT/EP2019/068798 WO2020011968A1 (en) 2018-07-12 2019-07-12 Anti-cd137 antibodies

Publications (4)

Publication Number Publication Date
JP2021525546A JP2021525546A (ja) 2021-09-27
JP2021525546A5 JP2021525546A5 (https=) 2022-07-20
JPWO2020011968A5 JPWO2020011968A5 (https=) 2022-07-20
JP7341217B2 true JP7341217B2 (ja) 2023-09-08

Family

ID=63273215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500559A Active JP7341217B2 (ja) 2018-07-12 2019-07-12 抗ｃｄ１３７抗体

Country Status (7)

Country Link
US (1) US12534534B2 (https=)
EP (1) EP3820570A1 (https=)
JP (1) JP7341217B2 (https=)
AU (1) AU2019301208B2 (https=)
CA (1) CA3106050A1 (https=)
GB (1) GB201811404D0 (https=)
WO (1) WO2020011968A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190022632A (ko) 2016-06-20 2019-03-06 에프-스타 베타 리미티드 Lag-3 결합 구성원
KR102664891B1 (ko) 2016-06-20 2024-05-13 에프-스타 테라퓨틱스 리미티드 Pd-l1 및 lag-3에 결합하는 결합 분자
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
JP7332627B2 (ja) 2018-04-25 2023-08-23 プロメテウス バイオサイエンシーズ，インク． 最適化された抗ｔｌ１ａ抗体
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
BR112021000282A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a cd137 e ox40
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
PL3820569T3 (pl) 2018-07-12 2025-07-14 Invox Pharma Limited Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
PH12021552002A1 (en) 2019-02-20 2022-09-19 Denali Therapeutics Inc Anti-trem2 antibodies and methods of use thereof
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
PE20221465A1 (es) 2020-01-13 2022-09-21 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos
EP4106880A4 (en) * 2020-02-17 2024-07-03 Board of Regents, The University of Texas System HUMAN 4-1BB AGONIST ANTIBODIES AND METHODS OF USE THEREOF
US20230242658A1 (en) * 2020-06-30 2023-08-03 Nona Biosciences (Suzhou) Co., Ltd. 4-1bb-binding protein and use thereof
US20250376535A1 (en) * 2022-06-28 2025-12-11 Beijing Starmab Biomed Technology Ltd Monospecific and multi-specific antibodies
EP4584300A1 (en) * 2022-09-06 2025-07-16 TJ Biopharma (Shanghai) Co., Ltd. Multispecific constructs and uses thereof
EP4592317A1 (en) * 2022-09-22 2025-07-30 ABlink Biotech Co., Ltd. Anti-4-1bb nanobody, preparation therefor, and use thereof
CN115850487B (zh) * 2022-12-19 2025-02-25 首都医科大学附属北京胸科医院 一种抗人cd137抗体、核酸分子及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017055398A2 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
WO2017182672A1 (en) 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
WO2018056821A1 (en) 2016-09-23 2018-03-29 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
WO2018091740A2 (en) 2016-11-21 2018-05-24 Alligator Bioscience Ab Novel antibodies and uses thereof

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2245404C3 (de) 1972-09-15 1978-08-31 Robert Bosch Gmbh, 7000 Stuttgart Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben
JPS531908B2 (https=) 1973-11-12 1978-01-23
JPS5746634B2 (https=) 1974-05-10 1982-10-04
JPS5146628A (ja) 1974-10-17 1976-04-21 Nippon Denso Co Teikoirisupaakupuragu
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
WO1995023874A1 (en) 1994-03-01 1995-09-08 Ludwig Institute For Cancer Research Determination of cancerous conditions by mage gene expression
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
ATE317437T1 (de) 1997-12-01 2006-02-15 Us Gov Health & Human Serv Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
DE19818214A1 (de) 1998-04-24 1999-10-28 Bosch Gmbh Robert Zündkerze für eine Brennkraftmaschine
DK1180123T3 (da) 1999-05-27 2008-10-13 Us Gov Health & Human Serv Immunkonjugater, der har höj bindingsaffinitet
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
JP4578025B2 (ja) 2001-07-06 2010-11-10 日本特殊陶業株式会社 スパークプラグ
JP2003228556A (ja) 2002-02-01 2003-08-15 Casio Comput Co Ltd 文書ファイル処理装置及びプログラム
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN103555733A (zh) 2005-01-05 2014-02-05 F-星生物技术研究与开发有限公司 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
WO2006088447A1 (en) 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
CA2600505C (en) 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP3241842B1 (en) 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
EP3103814A1 (en) 2007-11-26 2016-12-14 Bayer Intellectual Property GmbH Anti-mesothelin antibodies and uses therefor
DK2851374T3 (en) 2007-12-14 2017-06-19 Bristol Myers Squibb Co Binding molecules to the human OX40 receptor
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RU2526156C2 (ru) 2008-11-13 2014-08-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Cd37-иммунотерапевтическая комбинированная терапия и ее применения
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
US8460660B2 (en) 2009-03-24 2013-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
PE20141114A1 (es) 2010-12-20 2014-09-15 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
HK1204557A1 (en) 2012-05-31 2015-11-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
JP5276742B1 (ja) 2012-08-09 2013-08-28 日本特殊陶業株式会社 点火プラグ
CN104955845B (zh) 2012-09-27 2018-11-16 美国政府(由卫生和人类服务部的部长所代表) 间皮素抗体和引起有效的抗肿瘤活性的方法
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
EA037554B1 (ru) 2013-03-15 2021-04-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Анти-lag-3 связывающие белки
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof
EP3686219A1 (en) 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
WO2015198312A1 (en) 2014-06-24 2015-12-30 Ccam Therapeutics Ltd. Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
JP5902757B2 (ja) 2014-06-24 2016-04-13 日本特殊陶業株式会社 スパークプラグ
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN106716752B (zh) 2014-08-10 2019-01-04 费德罗-莫格尔点火公司 具有改进的密封的火花塞
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3623386B1 (en) * 2015-01-08 2022-04-13 BioNTech SE Agonistic tnf receptor binding agents
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
TW201632559A (zh) * 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
TW201642897A (zh) 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 Ｈｅｒ２結合劑治療
KR20170138574A (ko) 2015-05-04 2017-12-15 피어이스 파마슈티컬즈 게엠베하 항암 융합 폴리펩타이드
JP2018520650A (ja) 2015-05-21 2018-08-02 アリゲーター・バイオサイエンス・アーベー 新規のポリペプチド
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
JP6025921B1 (ja) 2015-06-22 2016-11-16 日本特殊陶業株式会社 スパークプラグ
KR20180029238A (ko) 2015-07-15 2018-03-20 피어이스 파마슈티컬즈 게엠베하 Lag-3에 특이적인 신규 단백질
CA2993177A1 (en) 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
WO2017025498A1 (en) 2015-08-07 2017-02-16 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for lag-3 and pd-1
HRP20201022T1 (hr) 2015-09-22 2020-10-16 Dingfu Biotarget Co., Ltd Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
KR101782487B1 (ko) 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
MA43260A (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
WO2017087901A2 (en) 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
KR20180096789A (ko) 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
KR102211384B1 (ko) 2016-03-18 2021-02-03 다이니폰 인사츠 가부시키가이샤 중간 전사 매체, 중간 전사 매체와 열전사 시트의 조합 및 인화물의 형성 방법
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
BR112018074453A2 (pt) 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
US20190106494A1 (en) 2016-06-13 2019-04-11 Askgene Pharma Inc. PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
KR20190022632A (ko) 2016-06-20 2019-03-06 에프-스타 베타 리미티드 Lag-3 결합 구성원
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102664891B1 (ko) 2016-06-20 2024-05-13 에프-스타 테라퓨틱스 리미티드 Pd-l1 및 lag-3에 결합하는 결합 분자
CN107523546A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的nk细胞及其用途
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EP3487883B1 (en) 2016-07-20 2023-01-04 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
GB201616699D0 (en) 2016-09-30 2016-11-16 Mab Designs Ltd Antibodies
WO2018115859A1 (en) * 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
JP7220161B2 (ja) 2017-05-26 2023-02-09 ノビミューン エスアー 抗ＣＤ４７ｘ抗メソテリン抗体およびそれを使用する方法
US20210340250A1 (en) 2017-05-30 2021-11-04 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
PL3820569T3 (pl) 2018-07-12 2025-07-14 Invox Pharma Limited Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
BR112021000282A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a cd137 e ox40
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
KR20220008316A (ko) 2019-05-14 2022-01-20 에프-스타 테라퓨틱스 리미티드 Lag-3/pd-l1 이중특이적 항체의 투여를 위한 투여 요법
CA3145523A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies
AU2022222299A1 (en) 2021-02-17 2023-09-07 F-Star Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
TW202246338A (zh) 2021-02-17 2022-12-01 英商適應生物治療有限公司 抗ＴＣＲδ可變1抗體
WO2022248380A1 (en) 2021-05-25 2022-12-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017055398A2 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
WO2017182672A1 (en) 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
WO2018056821A1 (en) 2016-09-23 2018-03-29 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
WO2018091740A2 (en) 2016-11-21 2018-05-24 Alligator Bioscience Ab Novel antibodies and uses thereof

Also Published As

Publication number Publication date
US12534534B2 (en) 2026-01-27
CA3106050A1 (en) 2020-01-16
WO2020011968A1 (en) 2020-01-16
US20210238299A1 (en) 2021-08-05
EP3820570A1 (en) 2021-05-19
AU2019301208B2 (en) 2026-02-12
TW202019964A (zh) 2020-06-01
JP2021525546A (ja) 2021-09-27
AU2019301208A1 (en) 2021-03-04
GB201811404D0 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
JP7341217B2 (ja) 抗ｃｄ１３７抗体
JP7690552B2 (ja) ＣＤ１３７抗原結合部位を含むＦｃ結合断片
US20250361312A1 (en) Fc binding fragments comprising an ox40 antigen-binding site
US20250368730A1 (en) Anti-mesothelin antibodies
TWI920016B (zh) Ox40結合分子
RU2824467C2 (ru) Fc-связывающие фрагменты, содержащие антигенсвязывающий сайт для cd137

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220324

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230419

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230829

R150 Certificate of patent or registration of utility model

Ref document number: 7341217

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350